GeneDx Holdings Corp. (NASDAQ:WGS) is under scrutiny as the Rosen Law Firm investigates potential securities claims on behalf of its shareholders. The investigation follows allegations from Grizzly Research that GeneDx engaged in fraudulent activities to exploit Medicaid and Medicare systems, allegedly inflating its revenue. This has led to a significant drop in the company's stock price, which fell by $4.84 per share, or 6.7%, closing at $67.18.
The Rosen Law Firm, known for its success in securities class actions, is preparing a class action to recover investor losses. The firm has a strong track record, having secured over $438 million for investors in 2019. Shareholders affected by the recent developments are encouraged to join the action to potentially recover their losses.
Amid these allegations, key executives at GeneDx have been involved in notable stock transactions. On July 29, 2025, Feeley Kevin, the Chief Financial Officer, sold 388 shares of Class A Common Stock at $105.31 each. Following this sale, he retains 3,757 shares. Similarly, Katherine Stueland, the CEO, sold 2,154 shares at the same price, leaving her with 3,440 shares.
Currently, GeneDx's stock is trading at $101.60, reflecting a decrease of 0.34% today. The stock has fluctuated between a low of $97.89 and a high of $103.42 during the trading day. Over the past year, the stock has seen a high of $117.75 and a low of $25.32. The company's market capitalization is approximately $2.92 billion, with a trading volume of 835,267 shares.
